Neumora, RayzeBio aiming to raise over $200 million in separate IPOs

11 Sep 2023
firstwordpharma.com
Phase 2IPOPhase 3
Neumora Therapeutics and RayzeBio on Monday each set terms for their initial public offerings (IPOs), saying they hope to raise roughly $264.8 million and $238.2 million, respectively. The momentum in biotech IPOs has experienced a slowdown since 2021, but the pricing of Neumora and RayzeBio's offerings may signal that the market is gradually recovering.
Neumora, which is focused on treating brain diseases, said it is offering 14.7 million shares in the IPO, which is expected to price between $16 and $18 a share. Proceeds from the IPO, coupled with its current resources, will be sufficient to meet its working-capital and capital-spending needs for at least the next 30 months, it added.
The company made its debut in 2021, backed by over $500 million in capital, including a $100-million equity investment from Amgen. Last year, it picked up another $112 million in Series B financing, to advance a pipeline of candidates targeting a range of neuropsychiatric disorders and neurodegenerative diseases.
Its lead asset navacaprant, also known as NMRA-140, is a kappa opioid receptor antagonistkappa opioid receptor antagonist currently in a Phase III study for major depressive disorder, and Phase II testing for neuropsychiatric disorders. It is also developing the V1aR antagonist NMRA-511 in Phase I for agitation in Alzheimer's disease, as well as for post-traumatic stress disorder and anxiety. The company has a clutch of preclinical assets as well, including the M4R modulator NMRA-M4R.
Meanwhile, a total of 14.4 million shares will be offered in RayzeBio's IPO, which is expected to price between $16 and $18 apiece. The company has a pipeline of radiopharmaceutical therapeutics, including the lead programme RYZ101, which is designed to deliver the radioisotope Actinium-225 to tumours expressing SSTR2. The therapy is currently being evaluated in the Phase III ACTION-1 study in patients with SSTR+ gastroenteropancreatic neuroendocrine tumours who have progressed following prior Lutetium-177-labelled somatostatin analogue therapy.
RayzeBio is also developing RYZ801 and RYZ811, a pair of radiopharmaceuticals that target GPC3, for the potential treatment of hepatocellular carcinoma.
For more, see Spotlight On: Late-stage biotechs join IPO queue.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.